THESE ARTICLES ARE COPYRIGHTED BY THE PUBLISHER
UNAUTHORIZED COPYING AND DISTRIBUTION IS PROHIBITED
Publications and Communications
Peer-reviewed
articles
1. Griebel G, Saffroy Spittler M, Misslin R, Vogel E, Martin JR
(1990) Serenics fluprazine (DU 27716) and eltoprazine (DU 28853) enhance
neophobic and emotional behaviour in mice. Psychopharmacology 102:
498-502. Pdf
2. Misslin R, Griebel G, Saffroy Spittler M, Vogel E (1990)
Anxiolytic and sedative effects of 5-HT1A ligands, 8-OH-DPAT and MDL
73005EF, in mice. NeuroReport 1: 267-270. Pdf
3. Griebel G, Saffroy Spittler M, Misslin R, Remmy D, Vogel E,
Bourguignon JJ (1991) Comparison of the behavioural effects of an adenosine A1/A2-receptor
antagonist, CGS 15943A, and an A1-selective antagonist, DPCPX. Psychopharmacology
103: 541-544. Pdf
4. Griebel G, Misslin R, Vogel E, Bourguignon JJ (1991)
Behavioral effects of rolipram and structurally related compounds in mice:
behavioral sedation of cAMP phosphodiesterase inhibitors. Pharmacology
Biochemistry and Behavior 39: 321-323. Pdf
5. Griebel G, Misslin R, Vogel E (1991) Behavioural effects of
selective A2 adenosine receptor antagonists, CGS 21197 and CGS
22706, in mice. NeuroReport 2: 139-140. Pdf
6. Griebel G, Misslin R, Pawlowski M, Vogel E (1991)
m-Chlorophenylpiperazine enhances neophobic and anxious behaviour in mice. NeuroReport
2: 627-629. Pdf
7. Bouchon R, Griebel G, Vogel E, Misslin R, Ropartz P (1992)
Prolactin similar to ectopic pituitary isograft restores responsiveness in
Snell dwarf mice. NeuroReport 3: 210-212. Pdf
8. Griebel G, Misslin R, Pawlowski M, Guardiola Lemaitre B,
Guillaumet G, Bizot Espiard J (1992) Anxiolytic-like effects of a selective
5-HT1A agonist, S20244, and its enantiomers in mice. NeuroReport
3: 84-86. Pdf
9. Moreau JL, Griebel G, Jenck F, Martin JR, Widmer U, Haefely WE
(1992) Behavioral profile of the 5HT1A receptor antagonist
(S)-UH-301 in rodents and monkeys. Brain Research Bulletin 29:
901-904. Pdf
10. Griebel G, Belzung C, Misslin R, Vogel E (1993) The
free-exploratory paradigm: An effective method for measuring neophobic
behaviour in mice and testing potential neophobia-reducing drugs. Behavioural
Pharmacology 4: 637-644. Pdf
11. Griebel G, Moreau J-L, Jenck F, Martin JR, Misslin R (1993)
Some critical determinants of the behaviour of rats in the elevated plus-maze. Behavioural
Processes 29: 37-47. Pdf
12. Griebel G, Moreau J-L, Jenck F, Misslin R, Martin JR (1994)
Acute and chronic treatment with 5-HT reuptake inhibitors differentially
modulate emotional responses in anxiety models in rodents. Psychopharmacology
113: 463-470. Pdf
13. Griebel G, Moreau JL, Jenck F, Mutel V, Martin JR, Misslin R
(1994) Evidence that tolerance to the anxiogenic-like effects of mCPP does not
involve alteration in the function of 5-HT2C receptors in the rat
choroid plexus. Behavioural Pharmacology 5: 642-645. Pdf
14. Blanchard DC, Griebel G, Blanchard RJ (1995) Gender bias in
the preclinical psychopharmacology of anxiety: Male models for (predominantly)
female disorders. Journal of Psychopharmacology 9: 79-82. Pdf
15. Griebel G, Blanchard DC, Jung A, Lee JC, Masuda CK, Blanchard
RJ (1995) Further evidence that the Mouse Defense Test Battery is useful for
screening anxiolytic and panicolytic drugs: Effects of acute and chronic
treatment with alprazolam. Neuropharmacology 34: 1625-1633. Pdf
16. Griebel G, Blanchard DC, Jung A, Blanchard RJ (1995) A model
of 'antipredator' defense in Swiss-Webster mice: Effects of benzodiazepine
receptor ligands with different intrinsic activities. Behavioural
Pharmacology 6: 732-745. Pdf
17. Griebel G, Blanchard DC, Agnes RS, Blanchard RJ (1995)
Differential modulation of antipredator defensive behavior in Swiss-Webster
mice following acute or chronic administration of imipramine and fluoxetine. Psychopharmacology
120: 57-66. Pdf
18. Griebel G, Blanchard DC, Jung A, Masuda CK, Blanchard RJ
(1995) 5-HT1A agonists modulate mouse antipredator defensive
behavior differently from the 5-HT2A antagonist pirenperone. Pharmacology
Biochemistry and Behavior 51: 235-244. Pdf
19. Griebel G (1995) 5-Hydroxytryptamine-interacting drugs in
animal models of anxiety disorders: More than 30 years of research. Pharmacology
and Therapeutics 65: 319-395. Pdf
20. Griebel G, Sanger DJ, Perrault G (1996) The Mouse Defense
Test Battery: Evaluation of the effects of non-selective and BZ-1 (w 1) selective,
benzodiazepine receptor ligands. Behavioural Pharmacology 7:
560-572. Pdf
21. Griebel G, Sanger DJ, Perrault G (1996) The use of the rat
elevated plus-maze to discriminate between non-selective and BZ-1 (w 1) selective,
benzodiazepine receptor ligands. Psychopharmacology 124: 245-254.
Pdf
22. Griebel G, Blanchard DC, Blanchard RJ (1996) Evidence that
the behaviors in the Mouse Defense Test Battery relate to different emotional
states: A factor analytic study. Physiology and Behavior 60:
1255-1260. Pdf
23. Griebel G, Blanchard DC, Blanchard RJ (1996)
Predator-elicited flight responses in Swiss-Webster mice: an experimental model
of panic attacks. Progress in Neuro-Psychopharmacology and Biological
Psychiatry 20: 185-205. Pdf
24. Griebel G, Blanchard DC, Rettori MC, Guardiola-Lemaître B,
Blanchard RJ (1996) Preclinical profile of the mixed 5-HT1A/5-HT2A
receptor antagonist S21357. Pharmacology Biochemistry and Behavior 54:
509-516. Pdf
25. Griebel G, Sanger DJ, Perrault G (1996) Further evidence for
differences between non-selective and BZ-1 (w 1) selective,
benzodiazepine receptor ligands in murine models of ''state'' and ''trait''
anxiety. Neuropharmacology 35: 1081-1091. Pdf
26. Griebel G (1996) Variability in the effects of 5-HT-related
compounds in experimental models of anxiety: evidence for multiple mechanisms
of 5-HT in anxiety or never ending story? Polish Journal of Pharmacology
48: 129-136. Pdf
27. Blanchard RJ, Griebel G, Guardiola-Lemaître B, Brush MM, Lee
J, Blanchard DC (1997) An ethopharmacological analysis of selective activation
of 5-HT1A receptors: The mouse 5-HT1A syndrome. Pharmacology
Biochemistry and Behavior 57: 897-908. Pdf
28. Blanchard RJ, Griebel G, Henrie JA, Blanchard DC (1997)
Differentiation of anxiolytic and panicolytic drugs by effects on rat and mouse
defense test batteries. Neuroscience and Biobehavioral Reviews 21:
783-789. Pdf
29. Griebel G, Sanger DJ, Perrault G (1997) Genetic differences
in the mouse defense test battery. Aggressive Behaviors 23:
19-31. Pdf
30. Griebel G, Perrault G, Sanger DJ (1997) A comparative study
of the effects of selective and non-selective 5-HT2 receptor subtype
antagonists in rat and mouse models of anxiety. Neuropharmacology 36:
793-802. Pdf
31. Griebel G, Perrault G, Sanger DJ (1997) Behavioural profiles
of the reversible monoamine-oxidase-A inhibitors befloxatone and moclobemide in
an experimental model for screening anxiolytic and anti-panic drugs. Psychopharmacology
131: 180-186. Pdf
32. Griebel G (1997) Serotonergic drugs in animal models of
anxiety: an update. Serotonin ID research alert 2: 251-257. Pdf
33. Griebel G, Perrault G, Sanger DJ (1997) CCK receptor
antagonists in animal models of anxiety: comparison between exploration tests,
conflict procedures and a model based on defensive behaviours. Behavioural
Pharmacology 8: 549-560. Pdf
34. Griebel G, Rodgers RJ, Perrault G, Sanger DJ (1997) Risk
assessment behaviour: Evaluation of utility in the study of 5-HT-related drugs
in the rat elevated plus-maze test. Pharmacology Biochemistry and Behavior
57: 817-827. Pdf
35. Blanchard DC, Griebel G, Rodgers RJ, Blanchard RJ (1998)
Benzodiazepine and serotonergic modulation of antipredator and conspecific
defense. Neuroscience and Biobehavioral Reviews 22: 597-612. Pdf
36. Griebel G, Perrault G, Sanger DJ (1998) Characterization of
the behavioral profile of the non peptide CRF receptor antagonist CP-154,526 in
anxiety models in rodents - Comparison with diazepam and buspirone. Psychopharmacology
138: 55-66. Pdf
37. Griebel G, Curet O, Perrault G, Sanger DJ (1998) Behavioral
effects of phenelzine in an experimental model for screening anxiolytic and
anti-panic drugs: correlation with changes in monoamine-oxidase activity and
monoamine levels. Neuropharmacology 37: 927-935. Pdf
38. Griebel G, Perrault G, Sanger DJ (1998) Limited
anxiolytic-like effects of non-benzodiazepine hypnotics in rodents. Journal
of Psychopharmacology 12: 356-365. Pdf
39. Griebel G, Perrault G, Sanger DJ (1999) Study of the
modulatory activity of BZ (w ) receptor ligands on defensive behaviors in mice: Evaluation of the
importance of intrinsic efficacy and receptor subtype selectivity. Progress
in Neuro-Psychopharmacology and Biological Psychiatry 23: 81-98. Pdf
40. Griebel G, Perrault G, Sanger DJ (1999) Differences in
anxiolytic-like profile of two novel nonbenzodiazepine BZ (w ) receptor agonists on
defensive behaviors of mice. Pharmacology Biochemistry and Behavior 62:
689-694. Pdf
41. Griebel G (1999) Is there a future for neuropeptide receptor
ligands in the treatment of anxiety disorders? Pharmacology and Therapeutics
82: 1-61. Pdf
42. Griebel G, Rodgers RJ, Perrault G, Sanger DJ (1999)
Behavioural profiles in the mouse defence test battery suggest anxiolytic
potential of 5-HT1A receptor antagonists. Psychopharmacology 144:
121-130. Pdf
43. Griebel G, Perrault G, Tan S, Schoemaker H, Sanger DJ (1999)
Pharmacological studies on synthetic flavonoids: comparison with diazepam.
Neuropharmacology 38: 965-977. Pdf
44. Griebel G, Perrault G, Sanger DJ (1999) Orphanin FQ, a novel
neuropeptide with anti-stress-like activity. Brain Research 836:
221-224. Pdf
45. Griebel G, Perrault G, Tan S, Schoemaker H, Sanger DJ (1999)
Comparison of the pharmacological properties of classical and novel BZ-w receptor ligands.
Behavioural Pharmacology 10: 483-495. Pdf
46. Griebel G, Cohen C, Perrault G, Sanger DJ (1999) Behavioral
effects of acute and chronic fluoxetine in Wistar-Kyoto rats. Physiology and
Behavior 67: 315-320. Pdf
47. Sanger DJ, Griebel G, Perrault G, Claustre Y, Schoemaker H
(1999) Discriminative stimulus effects of drugs acting at GABAA receptors:
Differential profiles and receptor selectivity. Pharmacology Biochemistry
and Behavior 64: 269-273. Pdf
48. Griebel G, Perrault G, Letang V, Granger P, Avenet P,
Schoemaker H, Sanger DJ (1999) New evidence that the pharmacological effects of
benzodiazepine receptor ligands can be associated with activities at different
BZ (w)
receptor subtypes. Psychopharmacology 146: 205-213. Pdf
49. Griebel G (1999) 5-HT1A receptor blockers as
potential drug candidates for the treatment of anxiety disorders. Drug News
& Perspectives 12: 484-490. Pdf
50. Griebel G, Belzung C, Perrault G, Sanger DJ (2000)
Differences in anxiety-related behaviours and in sensitivity to diazepam in
inbred and outbred strains of mice. Psychopharmacology 148:
164-170. Pdf
51. Belzung C, Le Guisquet AM, Griebel G (2000) b-CCT, a selective BZ-w1 receptor antagonist, blocks the anti-anxiety but not the amnesic action
of chlordiazepoxide in mice. Behavioural Pharmacology 11:125-131.
Pdf
52. Griebel G, Rodgers RJ, Perrault G, Sanger DJ (2000) The
effects of compounds varying in selectivity as 5-HT1A receptor
antagonists in three rat models of anxiety. Neuropharmacology 39:1848-1857.
Pdf
53. Andreatini R., Blanchard C., Blanchard R., Brandão M.L., Carobrez
A.P., Griebel G., Guimarães F.S., Handley S.L., Jenck F., Leite J.R.,
Rodgers J., Schenberg L.C., Da Cunha C. and Graeff F.G. (2001) The brain decade
in debate: II. Panic or anxiety? From animal models to a neurobiological basis.
Brazilian Journal of Medical and
Biological Research 34:145-154. Pdf
54. Blanchard D.C., Griebel G. and Blanchard R.J. (2001) Mouse
defensive behaviors: pharmacological and behavioral assays for anxiety and
panic. Neuroscience Biobehavioral Reviews
25:205-218. Pdf
55. Griebel G., Perrault G., Simiand J., Cohen C., Granger P.,
Decobert M., Françon D., Avenet P., Depoortere H., Tan S., Oblin A., Schoemaker
H., Evanno Y., Sevrin M., George P., Scatton S. (2001) SL651498: an
anxioselective compound with functional selectivity for a2- and a3-containing GABAA receptors. Journal of Pharmacological and Experimental Therapeutics 298:753-768. Pdf
56. Belzung C., El Hage W., Moindrot N. and Griebel G. (2001)
Behavioral and neurochemical changes following predatory stress in mice :
strain comparison and effects of anxiolytic drug treatments. Neuropharmacology 41:400-408. Pdf
57. Steinberg R., Alonso R., Griebel G., Bert L., Jung M.,
Oury-Donat F., Poncelet M., Gueudet C., Desvignes C., Le Fur G. and Soubrié P.
(2001) Selective blockade of neurokinin NK2 receptors produces antidepressant-like
effects associated with reduced CRF function. Journal of Pharmacological and Experimental Therapeutics 299:449-458. Pdf
58. Belzung C. and Griebel G. (2001) Measuring normal and
pathological anxiety in mice: a review. Behavioural
Brain Research 125:141-149. Pdf
59. Griebel G., Perrault G. and Soubrié P. (2001) Effects of
SR48968, a selective non-peptide NK2 receptor antagonist on
emotional processes in rodents. Psychopharmacology
158:241-251. Pdf
60. Griebel G., Moindrot N., Aliaga C., Simiand J. and Soubrié P.
(2001) Characterization of the profile of neurokinin-2 and
neurotensin receptor antagonists in the mouse defense test battery. Neuroscience and Biobehavioral
Reviews 25:619-626. Pdf
61. Serradeil-Le Gal C., Wagnon J., Simiand J., Griebel G.,
Lacour C., Guillon G., Barberis C., Brossard G., Soubrié P., Nisato D., Pascal
M., Pruss R., Scatton B., Maffrand J.-P. and Le Fur G. (2002) Characterization of (2S,4R)-1-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine
carboxamide (SSR149415), a Selective and Orally Active Vasopressin V1b
Receptor Antagonist. Journal
of Pharmacological and Experimental Therapeutics 300:1122-1130. Pdf
62. Griebel G., Simiand J., Steinberg R., Jung M., Gully D.,
Roger P., Geslin M., Scatton B., Maffrand J.-P. and Soubrié P. (2002) 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,
3-thiazol-2-amine Hydrochloride (SSR125543A), a Potent and Selective
Corticotrophin-Releasing Factor1 Receptor Antagonist. II.
Characterization in Rodent Models of Stress-Related Disorders. Journal of Pharmacological and Experimental
Therapeutics 301:333-345. Pdf
63. Gully D., Geslin M.,
Serva L., Fontaine E., Roger P., Lair C., Darre V., Marcy C., Rouby P.-E.,
Simiand J., Guitard J., Gout G., Steinberg R., Rodier D., Griebel G.,
Soubrié P., Pascal M., Pruss R., Maffrand J.-P. and Le Fur G. (2002) 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine
Hydrochloride (SSR125543A): A Potent and Selective Corticotrophin-Releasing
Factor1 Receptor Antagonist. I. Biochemical and Pharmacological
Characterization. Journal
of Pharmacological and Experimental Therapeutics 301:322-332. Pdf
64. Griebel G., Simiand J., Serradeil-Le Gal
C., Wagnon J., Pascal M., Scatton B., Maffrand J.-P. and Soubrié P. (2002) Anxiolytic- and antidepressant-like effects of the
non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest
an innovative approach for the treatment of stress-related disorders.
Proceedings of the National Academy of Sciences of the United States of
America 99: 6370-6375. Pdf - Press Releases
65. Steinberg R., Alonso R., Rouquier L., Desvignes C., Michaud J.-C.,
Cudennec A., Jung M., Simiand J., Griebel G., Emonds-Alt X., Le Fur G.
and Soubrié P. (2002) SSR240600
[(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichloro
phenyl)-2-morpholinyl]ethyl]-4-piperidinyl)-2-methylpropanamide], a centrally
active nonpeptide antagonist of the tachykinin neurokinin 1 receptor: II.
Neurochemical and behavioral characterization. The Journal of Pharmacology and Experimental
Therapeutics 303:1180-1188.
Pdf
66. Griebel G., Perrault G., Simiand J., Cohen C., Granger P.,
Depoortere H., Françon D., Avenet P., Schoemaker H., Evanno Y., Sevrin M.,
George P. and Scatton B. (2003) SL651498, a GABAA receptor agonist
with subtype-selective efficacy, as a potential treatment for generalized
anxiety disorder and muscle spasms. CNS Drug Reviews 9:3-20. Pdf
67. Blanchard D.C., Griebel G. and
Blanchard R.J. (2003) The mouse defense test battery: pharmacological and
behavioral assays for anxiety and panic. European Journal of Pharmacology 463: 97-116. Pdf
68. Ducottet C., Griebel G. and Belzung C. (2003) Effects of the
selective non-peptide corticotropin-releasing factor receptor 1 antagonist
antalarmin in the chronic mild stress model of depression in mice. Progress in
Neuro-Psychopharmacology & Biological Psychiatry 27:625-631. Pdf
69. Griebel G., Simiand J., Stemmelin
J., Serradeil-Le Gal C. and Steinberg R. (2003) The vasopressin V1b
receptor as a therapeutic target in stress-related disorders. Current Drug Targets – CNS
& Neurological Disorders 2:191-200.
Pdf
70. Holmes A., Heilig M.,
Rupniak N.M.J., Steckler T. and Griebel G. (2003) Neuropeptide systems as novel therapeutic targets for depression and
anxiety disorders. Trends in Pharmacological
Sciences 24:580-588. Pdf
71. Blanchard D.C., Griebel
G. and Blanchard R.J. (2003) Conditioning and residual emotionality effects
of predator stimuli: some reflections on stress and emotion. Progress in
Neuro-Psychopharmacology & Biological Psychiatry 27:1177-1185. Pdf
72. El Hage W., Peronny S., Griebel G. and
Belzung C. (2004) Impaired memory following predatory stress in mice is
improved by fluoxetine. Progress in Neuro-Psychopharmacology & Biological Psychiatry 28:123-128. Pdf
73. Farrokhi C.,
Blanchard D.C., Griebel G., Yang M., Gonzalez C., Markham C. and
Blanchard R.J. (2004) Effects of the CRF1 antagonist SSR125543A on
aggressive behaviors in hamsters. Pharmacology Biochemistry & Behavior 77:465-469. Pdf
74. Alonso R., Griebel
G., Pavone G., Stemmelin J., Le Fur G. and Soubrié P (2004). Blockade of
CRF1 or V1b receptors reverses stress-induced suppression
of neurogenesis in a mouse model of depression. Molecular Psychiatry 9:278-286.
Pdf
75. Griebel G., Simiand J., Stemmelin J., Serradeil-Le Gal C.,
Wagnon J., Steinberg R. and Soubrié P. (2004) Anxiolytic- and
antidepressant-like effects of non-peptide vasopressin V1b receptor
antagonists. Actualités de Chimie Thérapeutique 30:37-53. Pdf
76. Holmes A., Griebel G.,
Heilig M. and Steckler T. (2004) Response to Roesler et al.:
Neuropeptides and stress-related disorders – multiple targets and converging
concepts. Trends in Pharmacological Sciences 25:242-243.
Pdf
77. Boulay D., Depoortère R., Louis C., Perrault G., Griebel G.
and Soubrié P. (2004) SSR181507, a putative atypical antipsychotic with
dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social
interaction deficits induced by phenyclidine. Neuropharmacology 46:1121-1129.
Pdf
78. Overstreet D.H. and Griebel G. (2004) Antidepressant-like
effects of the CRF1 antagonist SSR125543 in an animal model of
depression. European Journal of Pharmacology 497:49-53. Pdf
79. Serradeil-Le Gal C., Derick S., Brossard G., Manning M., Simiand J.,
Gaillard R., Griebel G. and Guillon G. (2004) Functional and
pharmacological characterization of the first specific agonist and antagonist
for the V1b receptor in mammals. Stress 6:199-206. Pdf
80. Cohen C., Perrault G., Griebel G. and Soubrié P. (2005)
Nicotine-associated environmental stimuli maintain nicotine-seeking behaviour
in rats several weeks after nicotine withdrawal: reversal by the cannabinoid
(CB1) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology
30:145-155. Pdf
81. Stemmelin J., Lukovic L., Salomé N. and Griebel G. (2005)
Evidence that the lateral septum is involved in the antidepressant-like effects
of the vasopressin V1b receptor antagonist, SSR149415. Neuropsychopharmacology
30:35-42. Pdf
82. Blanchard R.J., Griebel G., Farrokhi C., Markham C.M., Yang
M. and Blanchard D.C. (2005) AVP V1b selective antagonist SSR149415
blocks aggressive behaviors in hamsters. Pharmacology Biochemistry &
Behavior 80:189-194. Pdf
83. Griebel G., Stemmelin J. and Scatton B. (2005) Effects of the
cannabinoid CB1 receptor antagonist, rimonabant, in models measuring different
aspects of emotional reactivity in rodents. Biological Psychiatry 57:261-267.
Pdf
84. Serradeil-Le Gal C., Wagnon J., Tonnerre B., Roux R., Garcia G., Griebel
G. and Aulombard A. (2005) An overview of SSR149415, a selective nonpeptide
vasopressin V1b receptor antagonist for the treatment of
stress-related disorders. CNS Drug Reviews 11:53-68. Pdf
85. Licata S.C., Platt D.M., Cook J.M., Sarma P.V.V.S, Griebel G.
and Rowlett J.K. (2005) Contribution of GABAA Receptor Subtypes to the
Anxiolytic-Like, Motor, and Discriminative Stimulus Effects of Benzodiazepines:
Studies with the Functionally Selective Ligand SL651498
[6-Fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1-yl-carbonyl)-2,9-dihydro-1H-pyridol[3,4-b]indol-1-one].
Journal of Pharmacological and
Experimental Therapeutics 313:1118–1125.
Pdf
86. Griebel G., Stemmelin J.,
Serradeil-Le Gal C. and Soubrié P. (2005) Non-Peptide Vasopressin V1b
Receptor Antagonists as Potential Drugs for the Treatment of Stress-Related
Disorders. Current
Pharmaceutical Design 11:1549-1559.
Pdf
87. Cohen C., Kodas E. and Griebel G.
(2005) CB1 receptor antagonists for the treatment of nicotine
addiction. Pharmacology Biochemistry & Behavior 81:387-395. Pdf
88. Overstreet D.H.
and Griebel G. (2005) Antidepressant-like effects of the vasopressin V1b
receptor antagonist SSR149415 in the Flinders Sensitive Line rat. Pharmacology
Biochemistry & Behavior 82:223-227. Pdf
89. Terranova J.P.,
Chabot C., Barnouin M.C., Perrault G., Depoortere R., Griebel G. and
Scatton B. (2005) SSR181507, a dopamine D2 receptor antagonist and
5-HT1A receptor agonist, alleviates disturbances of novelty
discrimination in a social context in rats, a putative model of selective
attention deficit. Psychopharmacology 181: 134–144. Pdf
90. Egashira N.,
Tanoue A., Higashihara F., Fuchigami H., Sano K., Mishima K., Fukue Y., Nagai
H., Takano Y., Tsujimoto G., Stemmelin J., Griebel G., Iwasaki K., Ikeda
T., Nishimura R. and Fujiwara M. (2005) Disruption of the Prepulse Inhibition
of the Startle Reflex in Vasopressin V1b Receptor Knockout Mice: Reversal by
Antipsychotic Drugs. Neuropsychopharmacology 30:1996–2005. Pdf
91. Depoortère R.
Dargazanli G., Estenne-Bouhtou G., Coste A., Lanneau C., Desvignes C., Poncelet
M., Heaulme M., Santucci V., Decobert M., Cudennec A., Voltz C., Boulay D.,
Terranova J.P., Stemmelin J., Roger P., Marabout B., Sevrin M., Vigé X., Biton
B., Steinberg R., Françon D., Alonso R., Avenet P., Oury-Donat F., Perrault G.,
Griebel G., George P., Soubrié P. and Scatton B. (2005) Neurochemical,
Electrophysiological and Pharmacological Profiles of the Selective Inhibitor of
the Glycine Transporter-1 SSR504734, a Potential New Type of Antipsychotic. Neuropsychopharmacology
30:1963–1985. Pdf
92. El Hage W., Griebel
G. and Belzung C. (2006) Long-term impaired memory following predatory
stress in mice. Physiology & Behavior 87:45-50. Pdf
93. Belzung
C.,Yalcin I., Griebel G., Surget A. and Leman S. (2006) Neuropeptides in
psychiatric diseases: An overview with a particular focus on depression and
anxiety disorders. CNS & Neurological Disorders - Drug Targets 5:135-145.
Pdf - Editorial
94. Salomé N.,
Stemmelin J., Cohen C. and Griebel G. (2006) Selective blockade of NK2 or NK3 receptors
produces anxiolytic- and antidepressant-like effects in gerbils. Pharmacology
Biochemistry & Behavior 83:533-539. Pdf
95. Salomé N.,
Stemmelin J., Cohen C. and Griebel G. (2006) Differential roles of
amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b
receptor antagonist, SSR149415, in rats. Psychopharmacology 187:237–244.
Pdf
96. Louis C., Cohen
C., Depoortère R. and Griebel G. (2006) Antidepressant-Like Effects of
the Corticotropin-Releasing Factor 1 Receptor Antagonist, SSR125543, and the
Vasopressin 1b Receptor Antagonist, SSR149415, in a DRL-72 s Schedule in the
Rat. Neuropsychopharmacology 31:2180–2187. Pdf
97. Biton B.,
Bergis O.E., Galli F., Nedelec A., Lochead A.W., Jegham S., Godet D., Lanneau
C., Santamaria R., Chesney F., Léonardon J., Granger P., Debono M.W., Bohme
G.A., Sgard F., Besnard F., Graham D., Coste A., Oblin A., Curet O., Vigé X.,
Voltz C., Rouquier L., Souilhac J., Santucci V., Gueudet C., Françon D.,
Steinberg R., Griebel G., Oury-Donat F., George P., Avenet P. and
Scatton B. (2007) SSR180711 : a novel selective α7 nicotinic receptor
partial agonist: (I) Binding and functional profile. Neuropsychopharmacology
32:1-16. Pdf
98. Pichat P.,
Bergis O.E., Terranova J.P., A. Urani, Duarte C., Santucci V., Gueudet C.,
Voltz C., Steinberg R., Stemmelin J., Oury-Donat F., Avenet F., Griebel G.
and Scatton B. (2007) SSR180711A, a novel selective α7 nicotinic receptor
partial agonist: (II) Efficacy in experimental models predictive of activity
against cognitive symptoms of schizophrenia. Neuropsychopharmacology 32:17-34.
Pdf
99. Kodas E., Cohen
C., Louis C. and Griebel G. (2007) Cortico-limbic circuitry for
conditioned nicotine-seeking behavior in rats involves endocannabinoid
signaling. Psychopharmacology 194:161-171. Pdf
100. Stemmelin J., Cohen
C., Terranova J.P., Lopez-Grancha M., Pichat P., Bergis O., Decobert M.,
Santucci V., Alonso R., Stahl S.M., Keane P., Avenet P., Scatton B., Le Fur G.
and Griebel G. (2008) Stimulation of the β3-adrenoceptor as a novel
treatment strategy for anxiety and depressive disorders. Neuropsychopharmacology
33:574-587. Pdf
101. Louis C.,
Stemmelin J., Boulay D., Bergis O., Cohen C. and Griebel G. (2008)
Additional evidence for anxiolytic- and antidepressant-like activities of
saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various
rodent-models. Pharmacology
Biochemistry & Behavior 89:36-45. Pdf
102. Overstreet
D.H., Stemmelin J. and Griebel G. (2008) Confirmation of antidepressant
potential of the selective β3 adrenoceptor agonist amibegron in an animal
model of depression. Pharmacology
Biochemistry & Behavior 89:623-626.
Pdf
103. Surget A.,
Saxe M., Leman S., Ibarguen-Vargas Y., Chalon S., Griebel G., Hen R. and Belzung
C. (2008) Drug-dependent requirement of hippocampal neurogenesis in a model of
depression and of antidepressant reversal. Biological
Psychiatry 64:293–301. Pdf
104. Boulay D.,
Pichat P., Dargazanli G., Estenne-Bouhtou G., Terranova J.P., Rogacki N., Louis
C., Stemmelin J., Coste A., Lanneau C., Desvignes C., Cohen C., Alonso R., Vigé
X., Biton B., Steinberg R., Sevrin M., Oury-Donat F., George P., Bergis O., Griebel G., Avenet P. and Scatton B.
(2008) Characterization of SSR103800, a selective inhibitor of the glycine
transporter-1 in models predictive of therapeutic activity in schizophrenia. Pharmacology Biochemistry &
Behavior 91:47-58. Pdf
105. Black M.D.,
Varty G.B., Arad M., Barak S., De Levie A., Griebel G. and Weiner I.
(2009) Procognitive and antipsychotic efficacy of glycine transport 1
inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia:
latent inhibition studies in the rat. Psychopharmacology
202:385–396. Pdf
106. Surget A.,
Wang Y., Leman S., Ibarguen-Vargas Y., Edgar N., Griebel G., Belzung C.
and Sibille E. (2009) Corticolimbic transcriptome changes are state-dependent
and region-specific in a rodent model of depression and of antidepressant
reversal. Neuropsychopharmacology 34:1363-1380. Pdf
107. Barak S., Arad
M., De Levie A., Black M.D., Griebel G. and Weiner I. (2009)
Pro-cognitive and antipsychotic efficacy of the α7 nicotinic partial
agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition
models of schizophrenia. Neuropsychopharmacology
34:1753–1763. Pdf
108. Boulay D.,
Bergis O., Avenet P. and Griebel G. (2010) The glycine transporter-1
Inhibitor SSR103800 displays a selective and specific antipsychotic-like
profile in normal and transgenic mice. Neuropsychopharmacology
35:416–427. Pdf
109. Overstreet
D.H., Naimoli V.M. and Griebel G. (2010) Saredutant, an NK2 receptor
antagonist, has both antidepressant-like effects and synergizes with
desipramine in an animal model of depression. Pharmacology Biochemistry & Behavior 96:206-210.
Pdf
110. Borelli K.G., Defensor E.B., Blanchard D.C.,
Blanchard R.J. and Griebel G. (2010) Effects of intra-hippocampal
injections of the NK2 receptor antagonist saredutant on the elevated plus maze,
and the mouse defense test battery. Neuroscience Letters 485:241–245. Pdf
111. Boulay D., Depoortere R., Louis C., Lacave M.,
Lucas M.T. and Griebel G. (2010) SSR181507, a dopamine D2
receptor and 5-HT1A receptor ligand: Evidence for mixed anxiolytic-
and antidepressant-like activities. Pharmacology
Biochemistry & Behavior 97:428-435.
Pdf
112.
Blanchard D.C., Griebel G., Pobbe R. and Blanchard R.J. (2011) Risk
assessment as an evolved threat detection and analysis process. Neuroscience Biobehavioral Reviews 35:991-998. Pdf
113.
Rogacki N., Lopez-Grancha M., Naimoli V., Potestio L., Stevens R.J., Pichat P.,
Bergis O.E., Cohen C., Varty G.B. and Griebel G. (2011) The neurokinin
NK2 antagonist, saredutant, ameliorates stress-induced conditions without
impairing cognition. Pharmacology
Biochemistry & Behavior 98:405-411.
Pdf
114. Urani A., Philbert J., Cohen C. and Griebel
G. (2011) The corticotropin-releasing factor 1 receptor antagonist,
SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, prevent
stress-induced cognitive impairment in mice. Pharmacology Biochemistry &
Behavior 98:425-431. Pdf
115. Philbert J., Pichat P., Beeské S.,
Decobert M., Belzung C. and Griebel G. (2011) Acute inescapable stress
exposure induces long-term sleep disturbances and avoidance behavior: A mouse
model of post-traumatic stress disorder (PTSD). Behavioural Brain Research
221:149-154. Pdf
116. Black M.D, Stevens R.J., Rogacki N.,
Featherstone R.E., Senyah Y., Stemmelin J., Pichat P., Arad M., Barak S., De
Levie A., Weiner I., Griebel G. and Varty G.B. (2011) AVE1625, a
Cannabinoid CB1 Receptor Antagonist, as a Co-Treatment with Antipsychotics for
Schizophrenia: Improvement in Cognitive Function and Reduction of
Antipsychotic-Side Effects in Rodents. Psychopharmacology 215:149-163.
Pdf
117. Surget A., Tanti A., Leonardo E.D,
Laugeray A., Rainer Q., Touma C., Palme R., Griebel G., Ibarguen-Vargas
Y., Hen R. and Belzung C. (2011) Antidepressants recruit new neurons to improve
stress response regulation. Molecular Psychiatry 16:1177-118. Pdf
118. Griebel G. and Beeské S. (2012) Is
there still a future for neurokinin 3 receptor antagonists as potential drugs
for the treatment of psychiatric diseases? Pharmacology & Therapeutics
133:116-123. Pdf
119. Griebel G., Pichat P., Pruniaux
M.P., Beeské S., Lopez-Grancha M., Genet E., Terranova J.P, Castro A., Sánchez
J.A., Black M., Varty G.B., Weiner I., Arad M., Barak S., De Levie A. and
Guillot E. (2012) SAR110894, a potent histamine H3-receptor
antagonist, displays procognitive effects in rodents. Pharmacology,
Biochemistry & Behavior 102:203-214. Pdf
120. Griebel G., Decobert M., Jacquet
A. and Beeské S. (2012) Awakening properties of newly discovered highly
selective H3 receptor antagonists in rats. Behavioural Brain Research 232:416-420. Pdf
121. Griebel G. and Holsboer F.
Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the
beginning? (2012) Nature Reviews Drug Discovery 11:462-478. Pdf
122. Philbert J., Pichat P., Belzung C. and Griebel
G. (2012) The CRF1 receptor antagonist SSR125543 attenuates
long-term cognitive deficit induced by acute inescapable stress in mice,
independently from the HPA axis. Pharmacology Biochemistry & Behavior
102:415-422. Pdf
123. Dournes C., Beeské S., Belzung C. and Griebel
G. (2013) Deep brain stimulation in treatment-resistant depression in mice:
Comparison with the CRF1 antagonist, SSR125543. Progress in
Neuro-Psychopharmacology & Biological Psychiatry 40:213-220. Pdf
124. Griebel G., Beeské S. and Stahl
S.M. (2012) The vasopressin V1b receptor antagonist SSR149415 in the
treatment of major depressive and generalized anxiety disorders: results from 4
randomized, double-blind, placebo-controlled studies. Journal of Clinical
Psychiatry 73:1403-1411. Pdf
125. Griebel G., Beeské S., Jacquet A.,
Laufrais C., Alonso R., Decobert M., Avenet P. and Françon D. (2013) Further
evidence for the sleep-promoting effects of 5-HT2A receptor
antagonists and demonstration of synergistic effects with the hypnotic,
zolpidem in rats. Neuropharmacology 70:19-26. Pdf
126. Philbert J., Belzung C. and Griebel G.
(2013) The CRF1 receptor antagonist SSR125543 prevents
stress-induced cognitive deficit associated with hippocampal dysfunction:
Comparison with paroxetine and D-cycloserine. Psychopharmacology 228:97-107.
Pdf
127. Griebel G. and Holmes A. (2013) 50
years of hurdles and hope in anxiolytic drug discovery. Nature Reviews Drug Discovery 12:667-687. Pdf
128. Gao Z., Hurst W.J., Czechtizky W.,
Francon D., Griebel G., Nagorny R., Pichat P., Schwink L., Stengelin S.,
Hendrix J.A. and George P.G. (2013) Discovery of a potent, selective, and
orally bioavailable histamine H3 receptor antagonist SAR110068 for
the treatment of sleep-wake disorders. Bioorganic & Medicinal Chemistry
Letters 23:6141-6145. Pdf
129. Boulay D., Ho-Van S., Bergis O., Avenet
P. and Griebel G. (2013) Phencyclidine decreases tickling-induced 50-kHz
ultrasound vocalizations in juvenile rats: a putative model of the negative
symptoms of schizophrenia? Behavioural Pharmacology 24:543-551. Pdf
130. Douma T.N., Millan M.J., Boulay D., Griebel
G., Verdouw P.M., Westphal K.G., Olivier B. and Groenink L. (2014) CRF1
receptor antagonists do not reverse pharmacological disruption of prepulse
inhibition in rodents. Psychopharmacology 231:1289-1303. Pdf
131. Griebel G., Ravinet-Trillou C.,
Beeské S., Avenet P. and Pichat P. (2014) Mice deficient in cryptochrome 1 (Cry1-/-)
exhibit resistance to obesity induced by a high-fat diet. Frontiers in
Endocrinology 5:49. Pdf
132. Belzung C., Turiault M. and Griebel G.
(2014) Optogenetics to study the circuits of fear- and depression-like
behaviors: A critical analysis. Pharmacology, Biochemistry & Behavior
122:144-157. Pdf
133. Philbert J., Beeské S., Belzung C. and Griebel
G. (2015) The CRF1 receptor antagonist SSR125543 prevents
stress-induced long-lasting sleep disturbances in a mouse model of PTSD:
Comparison with paroxetine and D-cycloserine. Behavioural Brain Research
279: 41-46. Pdf
134. Griebel G., Pichat P., Beeské S.,
Leroy T., Redon N., Jacquet A., Françon D., Bert L., Even L., Lopez-Grancha M.,
Tolstykh T., Sun F., Yu Q., Brittain S., Arlt H., He T., Zhang B., Wiederschain
D., Bertrand T., Houtmann J., Rak A., Vallée F., Michot N., Augé F., Menet V.,
Bergis O.E., George P., Avenet P., Mikol V., Didier M. and Escoubet J. (2015).
Selective blockade of the hydrolysis of the endocannabinoid
2-arachidonoylglycerol impairs learning and memory performance while producing
antinociceptive activity in rodents. Scientific Reports 5:7642. Pdf
135. Koob G.F and Griebel G. (2015) Pharmacology
Biochemistry and Behavior: The 2015 Transition. Pharmacology Biochemistry
& Behavior 131:iii. Pdf
136. Griebel G. (2015) Neuropeptide
receptor ligands for the treatment of schizophrenia: focus on neurotensin and tachykinins.
Current Pharmaceutical Design 21:3807-3812. Pdf
137. Griebel G., Pichat P., Boulay D.,
Naimoli V., Potestio L., Featherstone R., Sahni S., Defex H., Desvignes C.,
Slowinski F., Vigé X., Bergis O.E., Sher R., Kosley R., Kongsamut S., Black
M.D., Varty G.B. (2016) The mGluR2 positive allosteric modulator, SAR218645,
improves memory and attention deficits in translational models of cognitive
symptoms associated with schizophrenia. Scientific Reports 6:35320.
Pdf
138. Griebel G. (2017) Creativity in
large pharmaceutical research organizations: unleash the hungry drug hunter. British
Journal of Pharmacology 174: 2152-2153. Pdf
139. Griebel
G., Stemmelin J.,
Lopez-Grancha M., Fauchey V., Slowinski F., Pichat P., Dargazanli G.,
Abouabdellah A., Cohen C. and Bergis O.E (2018) The selective reversible FAAH
inhibitor, SSR411298, restores the development of maladaptive behaviors to
acute and chronic stress in rodents. Scientific Reports 8:2416. Pdf
140. Griebel G., Stemmelin J., Lopez-Grancha M.,
Boulay D., Boquet G., Slowinski F., Pichat P., Beeské S., Tanaka S., Mori A., Fujimura
M. And Eguchi J. (2019) The selective GSK3 inhibitor, SAR502250, displays neuroprotective
activity and attenuates behavioral impairments in models of neuropsychiatric symptoms
of Alzheimer’s disease in rodents. Scientific Reports 9:18045. Pdf
Book
1. Handbook of Anxiety And Fear. Eds
Blanchard R.J, Blanchard C.B., Griebel G. and Nutt D.J. Elsevier, The
Netherlands (2008). Cover - Buy
Book Chapters
1. Griebel G. and Sanger D.J. (1999) The Mouse Defense Test
Battery: An Experimental Model of Different Emotional States. In: Animal
Models of Human Emotion and Cognition. Edited by M. Haug and R.E. Whalen,
American Psychological Association, Washington, DC, pp. 75-85. Pdf
2. Griebel G., Perrault G. and Sanger D.J. (2000)
Subtype-selective benzodiazepine receptor ligands. In: Anxiolytics. Eds Briley M. and Nutt D. Birkhaüser Verlag,
Switzerland, pp. 77-94. Pdf
3. Belzung C., Griebel G., Dubois-Carmagnat F. and Darves-Bornoz
J.M. (2002) Amino acid transmitter systems. In: Biological Psychiatry.
Eds D'haenen H., den Boer J.A. and Willner P. John Wiley & Sons, Ltd, pp.
915-927. Pdf
4. Blanchard D.C., Blanchard R.J. and Griebel G. (2005) Defensive
Responses to Predator Threat in the Rat and Mouse. In: Current Protocols in
Neuroscience. Eds Crawley J., Gerfen C., Rogawski M., Sibley D., Skolnick
P. and Wray S. John Wiley & Sons, Inc., 8.19.1-8.19.20. Pdf
5. Griebel G. and Serradeil-Le Gal C. (2005) Non-peptide
vasopressin V1b receptor antagonists. In: Handbook of Stress and the Brain. Part 2 Stress: Integrative and
Clinical Aspects. Eds Steckler T., Kalin N.H. and Reul J.M.H.M. Elsevier,
The Netherlands, pp. 409-422. Pdf
6. Belzung C., Leman S., Griebel
G. (2008) Genetic factors underlying anxiety-behavior: a meta-analysis of
rodent studies involving targeted mutations of neurotransmission genes. In: Handbook of Anxiety And Fear. Eds Blanchard
R.J, Blanchard C.B., Griebel G. and Nutt D.J., Elsevier, The Netherlands, pp.
325-354. Pdf
7. Blanchard
R.J., Blanchard D.C., Griebel G., Nutt D. (2008) Introduction to the
handbook on fear and anxiety. In: Handbook of Anxiety And Fear. Eds
Blanchard R.J, Blanchard C.B., Griebel G. and Nutt D.J. Elsevier, The
Netherlands, pp. 3-10. Pdf
8. Turiault M., Cohen C. and Griebel G.
(2010) Tachykinins. In: Encyclopedia of Psychopharmacology. Ed Stolerman
I.P. Springer-Verlag, Berlin, Heidelberg, pp. 1301-1303. Pdf
9. Griebel G. and Beeské S. (2011) The
Mouse Defense Test Battery: a model measuring different facets of
anxiety-related behaviours. In: Mood and Anxiety Related Phenotypes in Mice:
Characterization Using Behavioral Tests. Volume II. Neuromethods, vol. 63,
pp. 97-106. Pdf
10. Griebel G. and Beeské S. (2014)
Mood and anxiety disorders. In: In Vivo Models for Drug Discovery, First
Edition. Eds Vela J.M, Maldonado R. and Hamon M. Wiley-VCH Verlag GmbH &
Co. KgaA, pp. 193-205. Pdf
11. Griebel G. and Beeské S. (2014)
Anxiety disorders. In: Behavioral Genetics of the Mouse: Volume II. Genetic
Mouse Models of Neurobehavioral Disorders. Eds Pietropaolo S., Sluyter F.
and Crusio W.E. Cambridge University Press, pp. 240-252. Pdf
Citations: 14880; h index = 64 (source Google Scholar, December 2019).
Oral Communications
1. Griebel G. (1999)
Traitements pharmacologiques des troubles liés au stress : point sur les
approches nouvelles. Stress et Immunité:
De la Clinique à la Recherche. Paris, October 5. Pdf.
2. Griebel G., Perrault G., Granger P., Decobert M.,Tan S., Avenet P., Evanno Y.,
Sevrin M., George P., Schoemaker H., Françon D., Depoortere H., Scatton B.
(2000) SL651498: a new anxiolytic with functional selectivity for GABAA2a
and GABAA3a receptor subtypes.
Society for Neuroscience, New
Orleans, USA, November 8. Pdf
3. Griebel G. (2001) Rationale for development of NK2 antagonists as anxiolytics and
antidepressants. Molecules, Medicines and
Mood: antidepressant development and use, BAP Midlands Regional Meeting,
Birmingham, UK, March 27. Pdf
4. Griebel G. (2001) Characterization of the profile of neuropeptide receptor
antagonists involved in the modulation of stress response using the mouse
defense test battery. IBNS Satellite Symposium on Defense,
Cancun, Mexico, April 25. Pdf
5. Griebel G. (2001) Brain Neurokinin-2 receptors as potential targets for
anxiolytics and antidepressants. European Behavioural Pharmacology Society
& European Brain and Behavior Society joint meeting, Marseille, France,
September 9. Pdf
6. Griebel G. (2003) The vasopressin V1b receptor as a therapeutic target in
stress-related disorders. Psychiatric Drug Discovery & Development,
Princeton, USA, June 24. Pdf
7. Griebel G. (2003) Anxiolytic- and antidepressant-like effects of non-peptide
vasopressin V1b receptor antagonists. Second Joint French-Swiss Meeting on
Medicinal Chemistry, Beaune, France, 1-4 July. Pdf
Posters
Kodas E., Cohen C., Louis C.
and Griebel G. (2005) Rimonabant infused into the shell of the nucleus
accumbens and the basolateral amygdala reduces nicotine-seeking behavior in
rats. 7ème Colloque de la Société des Neurosciences, May 18-20, Lille, France. Pdf
Pichat P., Terranova J.P.,
Bergis O., Griebel G., Scatton B. and Le Fur G. (2005). Characterization
of the cannabinoid CB1 receptor antagonist surinabant (SR147778) in models of
cognition in rodents. XVth ICRS Symposium
on Cannabinoids, Clearwater (Florida), June 24-27. Pdf
Boulay D., Depoortère R.,
Bergis O. and Griebel G. (2005) SSR240600 and saredutant, NK-1 and NK-2
receptor antagonists, respectively, increase social interaction in rats, in a
model sensitive to anxiolytic drugs. Behavioural
Pharmacology 16 (Supplement
1):S35. Pdf
Stemmelin J., Cohen C.,
Bergis O. and Griebel G. (2005) The α7nACh receptor agonist, SSR180711,
displays antidepressant-like effects in rodents. Behavioural Pharmacology 16
(Supplement 1):S47. Pdf
Louis C., Cohen C. and Griebel
G. (2005) Effects of three neurokinin antagonists at the NK-1, NK-2 or NK-3
receptor on the DRL 72s schedule in rats. Behavioural
Pharmacology 16 (Supplement
1):S43-44. Pdf
Urani A., Bergis O. and Griebel
G. (2005) SL65.0155, a 5HT4 partial agonist reverses memory
deficits induced by β25-35 amyloid peptide icv administration
in mice. European Neuropsychopharmacology
15 (Supplement 3): S389-390. Pdf
Stemmelin J., Cohen C.,
Scatton B., Le Fur G. and Griebel G. (2005) The β3 adrenoceptor
agonist, SR58611A, displays anxiolytic-like effects in rodents. Program No. 109.13. Abstract
Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience.
Washington, DC, USA, November 12-16. Pdf
Louis C., Terranova J.P.,
Decobert M., Bizot J.C., Françon D., Karson C., Alonso R., Cohen C. and Griebel
G. (2005) Surinabant, a New CB1 Receptor Antagonist, Displays Efficacy in
Animal Models of Attention Deficit/Hyperactivity Disorder. Neuropsychopharmacology 30
(Supplement 1): S173. ACNP 44th Annual
Meeting, December 11-15, Waikoloa, Hawaii. Pdf
Culig L., Legendre S.,
Minier F., Griebel G., Sahay A., Hen R. and Belzung C. (2015) Effects of
increasing adult hippocampal neurogenesis in mice during exposure to chronic
stress. Program No. 636.02. 2015
Neuroscience Meeting Planner. Chicago: Society for Neuroscience, 2015.
Online. Pdf
Reviewer for
the following journals:
Addiction Biology
Behavioural Brain Research
Behavioural Pharmacology
Brain Research
Brazilian Journal of Medical and Biological Research
CNS Drug Reviews
CNS Spectrums
Current Drugs
European Journal of Pharmacology
Expert Opinion on Emerging Drugs
Expert Opinion on Investigational Drugs
Genes Brain & Behavior
International Journal of Neuropsychopharmacology
Journal of Neural Transmission
Journal of Neuroscience
Journal of Psychopharmacology
Life Sciences
Molecular Brain Research
Nature Protocols
Neurobiology of Learning and Memory
Neuropeptides
Neuropharmacology
Neuropsychopharmacology
Neuroscience
Neuroscience & Biobehavioral Reviews
Neuroscience Letters
Pharmacology Biochemistry & Behavior
Physiology & Behavior
PNAS
Psychobiology
Psychopharmacology
Trends in Pharmacological Sciences
European
Research Council: Peer reviewer since 2013.
Editorial
Acivities:
Pharmacology Biochemistry & Behavior: Editor-in-Chief (2015-);
Associate Editor (2013-2014); Section Editor, Psychiatric Disorders
(2010-2014); Editorial Advisory Board (2002-2010)
Faculty Member, F1000Prime, Section Pharmacology & Drug Discovery
(2013-)
Current Psychiatry Reviews: Editorial Advisory Board Member (2014-)
World Journal of Psychiatry: Editorial Board (2011-)
Frontiers in Behavioral Neuroscience: Review Editor (2007-)
The Open Pharmacology Journal: Editorial Advisory Board (2007-)
Guest Editor:
Guest Editor: CNS & Neurological Disorders - Drug Targets, special
issue on “Neuropeptide systems as novel targets for psychiatric disorders”,
Volume 5, Number 2, April 2006.
Patents:
Drago F., Consoli D., Mazzola C., Micale V. and Griebel G. (18-04-2007) USE
OF PHENYLETHANOLAMINOTETRALINES FOR PREPARING ANXIOLYTIC DRUGS. EP1773316.
Griebel G. and Stemmelin J. (29-03-2007) ASSOCIATION OF ss3 RECEPTOR
AGONIST AND MONOAMINE REUPTAKE INHIBITORS, PHARMACEUTICAL COMPOSITION
CONTAINING SAME AND THERAPEUTIC USE THEREOF. WO2007034056.
Sanger D.J., Griebel G. and Perrault G. (2-06-2000) AGENT FOR
PROPHYLAXIS AND TREATMENT OF PANIC DISORDER. WO0030645.
